How HIV treatment could result in effective prevention.
As the number of HIV infections continues to surpass treatment capacity, new HIV prevention strategies are imperative. Beyond individual clinical benefits, by rendering an individual less infectious, expanding access to highly active antiretroviral therapy (HAART) could also have a larger public health impact of curbing new HIV infections. Recent guidelines have moved towards initiating HAART at higher CD4 cell counts, thus increasing the number of individuals in need of treatment. A new treatment strategy is wanting that can simultaneously curb the epidemic and provide necessary treatment to those most in need. A recent debate has centered on whether an expansion of free and universal treatment, regardless of CD4 cell count, could be a means of HIV prevention. In light of the growing access to HAART in resource-limited settings and increasing evidence suggesting the clinical and prevention benefits of initiating treatment at higher CD4 cell counts, it is conceivable that, in the future, HAART will be an integral part of both individual-level clinical treatment programs as well as public health-based HIV prevention interventions.
Venkatesh
Kartik K
KK
Department of Community Health, Division of Infectious Diseases, Department of Medicine, Alpert Medical School, Brown University/Miriam Hospital, RI, USA.
Lurie
Mark N
MN
Mayer
Kenneth H
KH
N Engl J Med. 1998 Mar 26;338(13):853-60
9516219
J Infect Dis. 2008 Jul 1;198(1):59-67
18498241
Lancet. 2009 Sep 19;374(9694):1023-1031
19709737
Curr Opin HIV AIDS. 2009 Jul;4(4):279-87
19532065
Trans R Soc Trop Med Hyg. 2008 Apr;102(4):310-1
18316103
J Infect Dis. 2006 Sep 15;194(6):734-9
16941338
Clin Infect Dis. 2006 Oct 1;43(7):939-41
16941380
CMAJ. 2008 Jul 1;179(1):13-4
18591515
Clin Infect Dis. 2006 Feb 1;42(3):383-4
16392085
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):632-41
16652038
N Engl J Med. 2003 May 1;348(18):1806-9
12724489
Lancet. 2009 Sep 5;374(9692):817-34
19709728
AIDS. 2003 Sep 5;17(13):1995-7
12960837
N Engl J Med. 2009 Apr 30;360(18):1815-26
19339714
AIDS. 2006 Jan 2;20(1):85-92
16327323
JAMA. 2008 Aug 6;300(5):555-70
18677028
J Infect Dis. 2005 May 1;191(9):1403-9
15809897
Clin Infect Dis. 2005 Jul 15;41(2):217-24
15983918
Lancet. 2008 Jul 26;372(9635):270-1
18657692
Clin Infect Dis. 2008 Dec 15;47(12):1580-6
18990069
AIDS. 2008 Sep;22 Suppl 3:S7-12
18845925
Emerg Themes Epidemiol. 2005 Sep 10;2:9
16153307
Lancet. 2008 May 10;371(9624):1603-11
18468544
J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92
17414934
AIDS Res Hum Retroviruses. 2005 May;21(5):343-57
15929696
Am J Public Health. 2002 Mar;92(3):388-94
11867317
Bull World Health Organ. 2007 Feb;85(2):152-5
17308737
AIDS. 2001 Jan 26;15(2):143-52
11216921
Science. 2008 Jul 25;321(5888):512-9
18653876
Lancet. 2002 Jun 15;359(9323):2059-64
12086758
AIDS. 2010 Mar 13;24(5):729-35
20154580
Clin Infect Dis. 2007 Feb 1;44(3):441-6
17205456
Ann Intern Med. 2003 Apr 15;138(8):680-1
12693893
J Infect Dis. 2007 Apr 1;195(7):951-9
17330784
AIDS. 2007 Jul;21 Suppl 4:S11-20
17620746
Arch Intern Med. 1994 Sep 12;154(17):1971-6
8074601
J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):27-35
17971714
Lancet. 2001 Aug 4;358(9279):404-9
11502340
AIDS. 2007 Jul;21 Suppl 4:S117-28
17620747
Health Policy. 2003 Apr;64(1):13-37
12644326
Ann Intern Med. 2007 Apr 17;146(8):591-601
17438318
Lancet Infect Dis. 2002 Aug;2(8):487-93
12150848
AIDS. 2008 Mar 12;22(5):617-24
18317003
J Infect Dis. 2008 May 15;197 Suppl 3:S252-60
18447611
Clin Infect Dis. 2002 May 15;34(10):1391-5
11981736
J Infect Dis. 2006 Sep 15;194(6):725-33
16941337
Antivir Ther. 2008;13 Suppl 2:1-13
18578063
Lancet. 2009 Jan 3;373(9657):7-9
19038440
Am J Public Health. 2001 Jul;91(7):1060-8
11441732
N Engl J Med. 2001 Mar 15;344(11):824-31
11248160
N Engl J Med. 1997 Nov 20;337(21):1485-90
9366579
AIDS. 2006 Mar 21;20(5):653-6
16514294
J Infect Dis. 2004 Sep 1;190(5):879-85
15295691
Lancet. 2009 Jan 3;373(9657):48-57
19038438
J Infect Dis. 2003 Feb 15;187(4):683-6
12599087
Sex Transm Dis. 2008 Dec;35(12):1009-10
18936724
Lancet. 2000 Jun 17;355(9221):2147-52
10902643
Am J Public Health. 2005 Jan;95(1):18-22
15623853
Lancet. 2003 Sep 13;362(9387):859-68
13678973
AIDS. 2008 Jul 11;22(11):1305-12
18580610
AIDS. 2007 May 11;21(8):965-71
17457090
Lancet. 2006 Aug 5;368(9534):505-10
16890837
JAMA. 2004 Jul 14;292(2):224-36
15249572
AIDS. 2007 Jul;21 Suppl 4:S55-63
17620754
Int J Tuberc Lung Dis. 2005 Oct;9(10):1062-71
16229216
Clin Infect Dis. 2010 Feb 1;50(3):416-25
20043752
Lancet Infect Dis. 2009 Oct;9(10):637-49
19778766
J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):275-83
11873077
N Engl J Med. 2010 Mar 18;362(11):967-70
20147707
HIV Med. 2006 Oct;7(7):442-50
16925730
AIDS. 2007 May 31;21(9):1185-97
17502729
Lancet. 2006 Mar 11;367(9513):817-24
16530575
Antivir Ther. 2007;12(4):543-51
17668563
N Engl J Med. 2000 Mar 30;342(13):921-9
10738050
Lancet. 2006 Jun 3;367(9525):1870-2
16753490
Ann Intern Med. 2000 Jul 4;133(1):21-30
10877736
Ann Intern Med. 2009 Aug 4;151(3):157-66
19620143
Lancet. 2006 Aug 5;368(9534):531-6
16890841
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101
16123689
AIDS Patient Care STDS. 2008 Apr;22(4):337-44
18422462
J Infect Dis. 2004 May 15;189(10):1785-92
15122514
AIDS. 2008 Jan 2;22(1):107-13
18090398
N Engl J Med. 2006 Sep 14;355(11):1141-53
16971720
J Infect Dis. 2006 Jul 1;194(1):11-9
16741877
AIDS. 1997 Aug;11(10):1249-54
9256943
Antivir Ther. 2004 Jun;9(3):375-84
15259900
J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):287-93
18845953
J Acquir Immune Defic Syndr. 2009 Nov;52 Suppl 1:S49-51
19858939
Lancet. 2007 Aug 4;370(9585):407-13
17659333
AIDS. 2000 Mar 10;14(4):415-21
10770544
JAMA. 2006 Aug 9;296(6):679-90
16896111
JAMA. 2010 May 12;303(18):1798-9
20460611